IRF3 and neoplasm: In our analysis using TCGA data, the expression of MB21D1, TMEM173, and TBK1 was not associated with prognosis, whereas high expression of IRF3 correlated with poor OS in MESO patients, indicating that IRF3 is strongly involved in tumor progression in MESO.